Evaluation of AMG 714 for Vitiligo

(

REVEAL

)

ITN Protocol #:

ITN086AI

Branded Name:

REVEAL

ClinicalTrials.Gov ID:

NCT04338581

Treatment Protocol #:

Therapeutic Area:

Autoimmune Disease

Current Status:

Follow-up

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Rho Scientist

Study Personnel:

Protocol Chair

Brett King, MD PhD brett.king@yale.edu

Work:

203-675-9818

Protocol Chair

Patti Tosta ptosta@immunetolerance.org

Work:

415-353-4421

Protocol Chair

Carolyn Bromstead cbromstead@immunetolerance.org

Work:

415-278-0702

Protocol Chair

Laura Cooney, PhD lcooney@immunetolerance.org

Work:

734-274-1149

Protocol Chair

Dawn Smilek, MD PhD dsmilek@immunetolerance.org

Work:

415-353-4308

Protocol Chair

Wendy Gao gaowe@mail.nih.gov

Work:

240-627-3471

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Protocol Chair

Marc Lytle Marc_Lytle@rhoworld.com

Work: